Surface Oncology’s $119.5 Million Initial Public Offering

Goodwin advised Surface Oncology, Inc. (Surface) on the pricing of its initial public offering Surface Oncology, Inc. (“Surface”) (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation antibody…

This content is for members only.
Login to Read More Join Now
Avatar

Author: Ambrogio Visconti

This content is for members only.
Login to Read More Join Now